General Anesthesia
Conditions
Keywords
Propofol, Population pharmacokinetics, Individualized administration
Brief summary
Propofol is a widely used sedative anesthetic, but there are large individual differences, which making different patients with different sensitivity to propofol. The aim of this study was to analyze the effects of age, height, body weight, Drinking, metabolic enzymes CYP2B6 and UGT1A9 on Pharmacological effects and pharmacokinetics of propofol, and to provide a reasonable reference for clinical anesthesia patients and evidence for individual dosage regimens.
Detailed description
Propofol is a widely used sedative anesthetic, but there are large individual differences, which making different patients with different sensitivity to propofol. In recent years, the concept of individualized administration came into being.Individual administration refers to according to the condition of patients,the drug's safety and efficacy, and pharmacokinetics, pharmacodynamics and clinical response ,then gives different dosing regimens for individual patients and promotes the development of rational drug use. Different people have differences metabolism of propofol, reported in the literature, genetic polymorphism, demographic characteristics, combined with drug and other variability factors, all of them will affect the pharmacokinetics and pharmacodynamics of propofol.The aim of this study was to analyze the effects of age, height, body weight, Drinking, metabolic enzymes CYP2B6 and UGT1A9 on Pharmacological effects and pharmacokinetics of propofol, and to provide a reasonable reference for clinical anesthesia patients and evidence for individual dosage regimens.
Interventions
DRUGPropofol
injection;2mg/kg;single-dose
Sponsors
Zhongyuan Xu
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* patients aged 18-60 years (including those aged 18 and 60) who underwent gastrointestinal endoscopy; * weight should not be less than (≥) 50kg, not more than (≤) 80kg. Body mass index (BMI) = body weight kg / \[(height m) 2\], in the normal range of 19 to 25; * American Society of Anesthesiologists (ASA) grading (Appendix I): I or II; * no heart, liver, lung, kidney, digestive tract, nervous system, mental disorders and other medical history, no blood and metabolic diseases and other medical history, no potential difficulties airway and special past history, * blood, urine, stool routine, liver and kidney function, blood lipids, ECG, chest X-ray and blood pressure normal, or abnormal but no clinical significance, the researchers believe that can be grouped. * agree and sign informed consent.
Exclusion criteria
* important organs have primary disease; * persons with mental or physical disabilities; * those suffering from neurological or mental illness, a history of epilepsy; * patients with cardiovascular or respiratory insufficiency and hypovolemia; * obese or those with dyslipidemia; * hereditary acute porphyria; * infections, especially those with respiratory and central infections; * language exchange barriers; * suspected or indeed a history of alcohol, drug abuse; especially long-term use of non-steroidal anti-inflammatory drugs, opioids, tranquilizers; * allergies, if the history of drugs or food allergies; or known to propofol, soybeans, peanuts, coconut oil allergy; * smoking history (smoking ≥ 5 per day); * 2 weeks before the trial had used all kinds of Chinese and Western medicine; * the last 3 months of blood donors and test blood donors; * other circumstances that the researcher thinks can not be grouped (eg, frail, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BIS | 210min | bispectral index monitoring |
Countries
China
Contacts
Primary Contactzhongyuan xu, Ph.D.
Backup Contactwanwen cao, master
Outcome results
None listed